諾和諾德公司成立于1923年，是一家全球領先的生物制藥公司，<\/i>總部位于丹麥。立足于在糖尿病領域的百年傳承，我們的使命是驅動改變，攜手戰勝嚴重慢性疾病。為達成這一目標，我們引領科研突破，擴大公司藥物可及性，并致力于預防及最終治愈疾病。諾和諾德在全球80個國家和地區擁有約7.84萬名員工，向全球約170個國家和地區提供產品和服務。諾和諾德中國官方網站：http:\/\/www.novonordisk.com.cn<\/a><\/p> \n

\n \n \n \n \n \n \n \n \n \n \n \n
<optgroup id="kgssg"></optgroup>
<center id="kgssg"></center>
久久久亚洲欧洲日产国码二区
[1] Wilding et al. N Engl J Med. 2021 Mar 18;384(11):989-1002.<\/span><\/p> <\/td> \n <\/tr> \n
[2] Garvey WT, et al. Nat Med. 2022 Oct; 28(10):2083-2091<\/span><\/p> <\/td> \n <\/tr> \n
[3] Rubino D, et al. JAMA. 2021 Apr 13;325(14):1414-1425.<\/span><\/p> <\/td> \n <\/tr> \n
[4] Wadden TA, et al. JAMA. 2021 Apr 13;325(14):1403-1413.<\/span><\/p> <\/td> \n <\/tr> \n
[5] Davies M, et al. Lancet. 2021 Mar 13;397(10278):971-984.<\/span><\/p> <\/td> \n <\/tr> \n
[6] Kadowaki T, et al. Lancet Diabetes Endocrinol. 2022 Mar;10(3):193-206.<\/span><\/p> <\/td> \n <\/tr> \n
[7] Lincoff MA, Brown-Frandson K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221-2232.<\/span><\/p> <\/td> \n <\/tr> \n
[8] Zhao, H., Jia, R. and Leng, A. (2022) 'EPH55 the prevalence of obesity and its implications in China: A narrative review of literature', Value in Health, 25(12). doi:10.1016\/j.jval.2022.09.977.<\/span><\/p> <\/td> \n <\/tr> \n
[9] 中國醫療保健國際交流促進會營養與代謝管理分會,中國營養學會臨床營養分會,中華醫學會糖尿病學分會,中華醫學會腸外腸內營養學分會,中國醫師協會營養醫師專業委員會,中國超重\/肥胖醫學營養治療指南(2021).中國醫學前沿雜志(電子版).2021;13(1):1-55.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p> \n
\n<\/div>"]; $("#dvExtra").html(content_array[0]);})();
<center id="kgssg"></center>